P. Szczypa

Psoriasis is a common skin disease, and clinical trials are a way of measuring how effective different treatments for psoriasis are. During such trials, researchers generally use specific methods for measuring improvements in patients’ symptoms and quality of life. These include the Psoriasis Area Severity Index (PASI, for which the lower the score, the worse the severity of the disease), the Physician Global Assessment (PGA) and the Dermatology Life Quality Index (DLQI).

Summary????????????,?????????????????????????????????,??????????????????????????????????,????????????????(PASI,????,??????)?????????(PGA)??????????(DLQI)???????????????????,????????????????????????????,????????????????????????????,??????“??”????????(????)????????????PASI?DLQI???????????????6119????,?128????“??”??????????????????75??85???????????PASI???6.3(?120??)?PASI??????75????????????????,80??????????,??????????????????????????????????????????????????????,????????

Patient-reported outcomes in psoriasis studies are assessed at specific study time points. If a treatment has not become effective by a certain time point, it may increase the likelihood of patients being dissatisfied and leaving a clinical study. Generate evidence concerning the number of patients dropping out of etanercept trials over time including PASI and DLQI data. Data from psoriasis patients in ten trials with etanercept were pooled.